Effect of intravenous lidocaine on short-term pain after hysteroscopy: a randomized clinical trial

Xuan Peng, Yuzi Zhao, Yeda Xiao, Liying Zhan, Huaxin Wang

* Renmin Hospital of Wuhan University, Department of Anesthesiology, Hubei, China
b Renmin Hospital of Wuhan University, Department of Obstetrics and Gynecology, Hubei, China

Received 1 December 2019; accepted 1 November 2020
Available online 6 February 2021

**KEYWORDS**
Anesthesia; Hysteroscopy; Lidocaine; Postoperative pain; Propofol

**Abstract**

**Background:** The role of intravenous lidocaine infusion in endoscopic surgery has been previously evaluated for pain relief and recovery. Recently, it has been shown to reduce postoperative pain and opioid use in patients undergoing endoscopic submucosal dissection. Similar to endoscopic submucosal dissection, operative hysteroscopy is also an endoscopic surgical procedure within natural lumen. The present study was a randomized clinical trial in which we evaluated whether intravenous lidocaine infusion would reduce postoperative pain in patients undergoing hysteroscopic surgery.

**Objective:** To evaluate whether intravenous lidocaine infusion could reduce postoperative pain in patients undergoing operative hysteroscopy.

**Methods:** Eighty-five patients scheduled to undergo elective hysteroscopy were randomized to receive either an intravenous bolus of lidocaine 1.5 mg.kg⁻¹ over 3 minutes, followed by continuous infusion at a rate of 2 mg.kg⁻¹.h⁻¹ during surgery, or 0.9% normal saline solution at the same rate. The primary outcome was to evaluate postoperative pain by Visual Analog Scale (VAS). Secondary outcomes included remifentanil and propofol consumption.

**Results:** In the lidocaine group, the VAS was significantly lower at 0.5 hour (p = 0.008) and 4 hours (p = 0.020). Patients in the lidocaine group required less remifentanil than patients in the control group (p < 0.001). However, there was no difference between the two groups in the propofol consumption. The incidence of throat pain was significantly lower in the lidocaine group (p = 0.019). No adverse events associated with lidocaine infusion were discovered.

**Conclusion:** Intravenous lidocaine infusion as an adjuvant reduces short-term postoperative pain in patients undergoing operative hysteroscopy.

© 2021 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Operative hysteroscopy is performed under General Anesthesia (GA), which benefits both physicians and patients. First, GA can reduce potential difficulties of intrauterine access compared with local anesthesia. Second, although a few studies have reported that non-pharmacological approaches to pain control for hysteroscopic procedures (including distraction methods and physical stimuli) have contributed to improving patient satisfaction, hysteroscopy continues to be painful for a very high percentage of patients. Obviously, GA has been demonstrated to alleviate patients' experience of pain during hysteroscopy.

Intraoperative lidocaine infusion has been widely accepted as an alternative to GA, as it can achieve opioid sparing, good pain relief, decreased postoperative nausea and vomiting, and excellent recovery. Furthermore, recent studies have shown that intravenous lidocaine infusion can reduce postoperative pain and opioid requirements in patients undergoing Endoscopic Submucosal Dissection (ESD). Similar to ESD, operative hysteroscopy is an endoscopic procedure within natural lumens. However, to the best of our knowledge, the efficacy of intravenous lidocaine in operative hysteroscopy has not been fully elucidated. Therefore, our study explored whether the administration of intravenous lidocaine can reduce postoperative pain, and propofol and remifentanil requirements in patients undergoing operative hysteroscopy.

Methods

Study population

The study protocol was conducted in compliance with the Helsinki Declaration and approved by the Hospital Ethics Committee of Renmin Hospital of Wuhan University. Written informed consent was obtained from 85 patients with an American Society of Anesthesiologists (ASA) classification of I–II undergoing operative hysteroscopy. The exclusion criteria were as follows: less than 18 years old; hypersensitivity to lidocaine; only performing diagnostic hysteroscopy; chronic abuse of opioid or nonsteroidal anti-inflammatory drug; chronic pain; mis- or lack of understanding of oral information about the study; other severe systemic diseases; and serious surgical complications. The study was registered under the Clinical Trials Register number ChiCTR1800016857.

Study group

Patients were categorized into two study groups using a random number table method performed by an Independent Anesthetist (IA) not involved in the treatment or follow up. The study drugs were prepared in syringes with an identical appearance by the same IA as follows: a 20 mL syringe contained 1% lidocaine solution or 0.9% normal saline solution (for the bolus), and a 50 mL syringe contained 1% lidocaine solution or 0.9% normal saline solution (for the continuous infusion). The treatment and follow-up anesthetists were all blinded to patient assignment until analysis completion. The IA would cease the blinding if the patient experienced abnormal conditions (such as serious complications) during the trial. All operative procedures were performed by the same surgeon, including the same hysteroscopic instrumentation.

Interventions

All patients received the study drugs prepared by IA with a bolus dose of 0.15 mL.kg\(^{-1}\) over 3 minutes prior to anesthesia induction, followed by continuous infusion at a rate of 0.2 mL.kg\(^{-1}\).h\(^{-1}\) until the end of the surgery. Patients were treated under the same anesthetic protocol without premedication. Standard monitoring included five-lead electrocardiography, oxygen saturation, noninvasive blood pressure, continual end-tidal carbon dioxide and Narcotrend (NTI) monitoring (MT Monitor Technik GmbH & Co., KG, D-24576 Bad Bramstedt, Germany). The Narcotrend Index (NTI) determined by the Narcotrend monitoring system is a dimensionless continuous variable ranging from 0 to 100 that reflects the depth of anesthesia. Based on the NTI, the depth of anesthesia ranges from stage A (awake) to stage F (very deep anesthesia), with stage D (37–64) indicating the routine depth of anesthesia for surgery.

Anesthesia was induced with propofol 2.5 mg.kg\(^{-1}\) and then with remifentanil 1.5 µg.kg\(^{-1}\) within one minute followed by the placement of a paraffin oil-lubricated laryngeal mask (ALMA type, Hangzhou Fu Shan Medical Appliances Co., Ltd. China). The specific size of advanced laryngeal mask airway (ALMA) was selected according to the weight of the patient (3# for 30–50 kg; 4# for 50–70 kg; 5# for 70–100 kg), the intracuff pressure of ALMA was the pressure that has been set at the factory (< 2 cm H\(_2\)O). We did not deflate before inserting the laryngeal mask, and generally did not inflate after inserting it. If the airway pressure is too high (more than 30 mmHg) or obviously leaking in mechanical ventilation after implantation, adjust the position of the laryngeal mask or proper inflation of air (less than 20 mL), observe the airway pressure, and check the end-breathing carbon dioxide partial pressure to ensure the correct position. 180-degree rotation was used for insertion of laryngeal mask by all anesthesiologists.

Patients were placed on given mechanical ventilation or were converted to assisted ventilation when they resumed spontaneous breathing. Anesthesia was maintained with continuous remifentanil and propofol infusion. Remifentanil was adjusted at a rate of 5–10 µg.kg\(^{-1}\).h\(^{-1}\), and the rate of propofol was adjusted according to the following NTI target values: during maintenance in a range from 37–64; 5 minutes before the end of surgery in a range from 65–79. In the case of intraoperative patient movement, additional remifentanil (1 µg.kg\(^{-1}\)) was injected immediately. Anesthesia was performed by the attending anesthesiologist for more than 5 years.

Outcomes and adverse events observation

Mean Blood Pressure (MAP), Heart Rate (HR), and NTI data were collected at six separate time points: before intravenous the study drugs prepared by IA e (T0); before anesthesia induction (T1); 5 and 10 minutes after surgery (T2 and T3); at the end of surgery (T4); and at the time of
laryngeal mask removal (T5). The total administered doses of remifentanil and propofol were recorded. Postoperative pain at rest was evaluated at 0.5 hour (T6), 4 hours (T7), and 24 hours (T8) after surgery by the visual analogue scale (VAS, 0 = no pain, 10 = unbearable pain). In the case of a VAS score ≥ 6, 50 mg of flurbiprofen was given intravenously. The incidence of throat pain was assessed using the VAS within 24 hours after surgery (any VAS score ≥ 2 was considered to represent a sore throat). The incidence of postoperative nausea or vomiting was also recorded up to 24-hours after the procedure.

**Statistical analysis**

The primary outcome variable was postoperative pain. The sample size was calculated based on the 0.5 hour postoperative VAS score of 5 patients (mean = 2.3; Standard Deviation – SD = 1.5) administered saline in a preliminary study. To demonstrate a 35% difference in the mean VAS score at 0.5 hour postoperatively between the two groups with a two-tailed α of 0.05 and a power of 80%, 36 candidates in each group were required. To compensate for the possibility of dropout for various reasons, we initially enrolled 85 patients in total for randomization. Statistical analysis was performed using GraphPad Prism version 6 (GraphPad Software Inc.). The Kolmogorov-Smirnov test was used to test the assumption of normal distribution. Normally distributed data are reported as mean ± SD and were compared among groups using unpaired t-test. Non-normally distributed data are reported as median (minimum–maximum) and were compared between groups using the Mann-Whitney U test. Repeated-measured data within the group, such as VAS, HR, MBP, and NIT were analyzed with two-way analysis of variance. When the interaction was statistically significant, sidak’s multiple comparisons test was performed. Categorical data were compared between groups with Chi-Square test. p-values less than 0.05 were considered to represent a statistically significant difference.

**Results**

The study flowchart is shown in Figure 1. Of 98 patients assessed for eligibility, 85 patients were enrolled and randomly assigned to two groups. Five patients (2 in Group L and 3 in Group C) were excluded from the analysis because only diagnostic hysteroscopy or uterine perforation was performed. Patient characteristics were similar between the groups (Table 1). For MAP, HR and NTI data at the corresponding time points no significant differences were found between the two groups (Figure 2).

Details regarding VAS scores, drugs administered, and postoperative events were shown in Table 2. In the lidocaine group, the VAS was significantly lower at 0.5 hour (p = 0.008) and 4 hours (p = 0.020) postoperatively, compared to the control group. The total administered dose of remifentanil was 13% lower in Group L than in Group C, 232 (185–410) vs. 259 (190–420); p < 0.001. There was no difference between the two groups in the propofol requirement. No patients were given flurbiprofen after surgery. Regarding to postoperative effects, the lidocaine group had less throat pain (22.5% vs. 47.5%, p = 0.019). The groups did not differ with respect to the incidence of nausea or vomiting. No case of lidocaine-related local anesthetic systemic toxicity was reported.
Table 1 Baseline characteristics of study subjects.

|                          | Group L (n = 40)       | Group C (n = 40)       | p-value |
|--------------------------|------------------------|------------------------|---------|
| Age (years)              | 31.38 ± 7.37           | 32.85 ± 7.73           | 0.385   |
| Weight (kg)              | 50 (40–78)             | 51 (42–82)             | 0.206   |
| Height (cm)              | 160.10 ± 7.05          | 159.20 ± 8.19          | 0.600   |
| ASA physical status, n (%) |                       |                        | 0.485   |
| I                        | 24 (60%)               | 27 (67.5%)             |         |
| II                       | 16 (40%)               | 13 (32.5%)             |         |
| Surgical indication, n (%) |                       |                        | 0.819   |
| Polyp                    | 15 (37.5%)             | 17 (42.5%)             |         |
| Intrauterine adhesion    | 11 (27.5%)             | 9 (22.5%)              |         |
| Submucous myoma          | 8 (20%)                | 10 (25%)               |         |
| Placenta remnant         | 3 (7.5%)               | 1 (2.5%)               |         |
| Cesarean scar pregnancy  | 1 (2.5%)               | 2 (5%)                 |         |
| Uterine septum           | 2 (5%)                 | 1 (2.5%)               |         |
| Duration of surgery (min)| 25 (18–55)             | 25 (15–48)             | 0.357   |

Values are shown as mean ± SD, median (minimum–maximum) or number of patients (proportion). ASA, American Society of Anesthesiologists.

Discussion

Hysteroscopic procedures could be performed under mild sedation, local anesthesia, or GA. In this randomized, double-blinded, placebo-controlled trial, we selected GA for use during operative hysteroscopy, with intravenous lidocaine administered as a bolus of 1.5 mg.kg⁻¹ and then a continuous infusion at 2 mg.kg⁻¹. h⁻¹. We found that this strategy reduces the severity of short-term postoperative pain. Moreover, lidocaine administration also reduces the remifentanil requirement and the incidence of throat pain during operative hysteroscopy.

Intravenous lidocaine infusion has shown efficacy in controlling postoperative pain. The analgesic mechanisms are multifactorial, including sodium channel blockade, reduction in spinal cord sensitivity, synergistic effects with the GA agents and intrinsic systemic anti-inflammatory properties. The analgesic efficacy of intravenous lidocaine...
have been observed mainly in abdominal surgeries, including colectomy, gastrectomy, and cholecystectomy. Moreover, Kim et al. confirmed the postoperative analgesic effects of intravenous lidocaine after ESD, an endoscopic surgical procedure with natural lumens similar to operative hysteroscopy. They also estimated that the analgesic effects of lidocaine were mainly on visceral pain. Therefore, we hypothesized that intravenous lidocaine would be beneficial for controlling visceral pain caused by operative hysteroscopy. In our study, administration of intravenous lidocaine resulted in reduced earlier postoperative hypogastric pain intensity and less remifentanil consumption during operative hysteroscopy, which is consistent with a previous study reporting that intravenous lidocaine had a positive impact on pain scores in the early postoperative phase. It has been confirmed that the half-life of lidocaine is only 1.5–2 hours after bolus injection. This may explain why analgesic effects were noted in the earlier postoperative phase rather than at 24 hours postoperatively in our study.

Remifentanil is a preferred drug for endoscopy because of its rapid onset and offset of action, and minimal adverse effects on cardiovascular and respiratory parameters. To observe earlier postoperative analgesic effects of intravenous lidocaine, another advantage of remifentanil is its ability to avoid interference with the use of other opioid drugs. The administration of intravenous lidocaine has been shown to have an opioid sparing effect during GA, including on fentanyl, sufentanil, and morphine. In a recent study, a remifentanil-sparing effect of intravenous lidocaine in the intraoperative period was found, which is consistent with our findings. However, another study reported that perioperative intravenous lidocaine infusion had no significant effect on the remifentanil requirement during hypotensive anesthesia for an elective transphenoidal endoscopic hypophyseal adenoma excision procedure. Previous studies reported that intravenous lidocaine had a propofol-sparing effect during GA. In this study, we ensured that each patient was at a constant anesthetic depth during surgery via Narcotrend monitoring, and we found that there was no difference in the propofol requirement between the two groups. These differences were likely due to the distinct types of surgery performed and different regimes for anesthetic management.

We used a laryngeal mask for mechanical ventilation or assisted ventilation to ensure respiratory safety in this study. In addition, placement of the laryngeal mask could also provide us with another way to observe the analgesic effects of lidocaine. The administration of intravenous lidocaine reduced the incidence of throat pain caused by the laryngeal mask from 47.5% to 22.5% in this study. Our observation is in keeping with the finding of several studies showing that the administration of intravenous lidocaine was effective in reducing throat pain after ESD and postoperative throat soreness caused by tracheal intubation. Last, we did not observe any significant differences in the incidence of postoperative nausea or vomiting, which is consistent with previous reports.

There are some limitations to our study. We did not measure the plasma level of lidocaine in our patients. However, the protocol for administering a loading dose followed by the continuous intravenous infusion of lidocaine during GA has been used previously at several centers and reported to result in a level well below the toxic level. Another limitation is the small number of patients. A larger-scale trial will provide further details to validate our findings. Finally, our unit did not have the nociception level index or analgesia nociception index monitoring equipment. The use of these devices may provide more accurate results in future studies.

In conclusion, intravenous lidocaine infusion as an adjuvant reduces short-term postoperative pain in patients undergoing operative hysteroscopy.

Conflicts of interest
The authors declare no conflicts of interest.

Acknowledgements
The authors thank all the patients and staff of this study for their important contributions. This study was supported by the Natural Science Foundation of Hubei Province (no. 2019CFC853) and the China Scholarship Council (no. 201706275133).

References
1. Munro MG, Brooks PG. Use of local anesthesia for office diagnostic and operative hysteroscopy. J Minim Invasive Gynecol. 2010;17:709–18.
2. Amer-Cuenca JJ, Marin-Buck A, Vitale SG, et al. Nonpharmacological pain control in outpatient hysterectomies. Minim Invasive Ther Allied Technol. 2019;1–10.
3. Bajracharya JL, Subedi A, Pokhare K, et al. The effect of intraoperative lidocaine versus esmolol infusion on postoperative analgesia in laparoscopic cholecystectomy: a randomized clinical trial. BMC Anesthesiol. 2019;19:198.
4. Krank P, Jokinen J, Pace NL, et al. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery. Cochrane Database Syst Rev. 2015;7:CD009642.
5. Kim JE, Choi JB, Koo BN, et al. Efficacy of intravenous lidocaine during endoscopic submucosal dissection for gastric neoplasm: a randomized, double-blind, controlled study. Medicine (Baltimore). 2016;95:e3593.
6. Esteve JP. Intravenous lidocaine. Best Pract Res Clin Anaesthesiol. 2017;31:513–21.
7. Kurabe M, Furue H, Kohno T. Intravenous administration of lidocaine directly acts on spinal dorsal horn and produces analgesic effect: An in vivo patch-clamp analysis. Sci Rep. 2016;6:26253.
8. De Oliveira CM, Issy AM, Sakata RK. Intraoperative intravenous lidocaine. Rev Bras Anestesiol. 2010;60:325–33.
9. Lee MW, Or DY, Tsang AC, et al. Intravenous lignocaine infusion facilitates acute rehabilitation after laparoscopic colectomy in the Chinese patients. Hong Kong J Med. 2017;23:441–5.
10. Yon JH, Choi GJ, Kang H, et al. Intraoperative systemic lidocaine for pre-emptive analgesics in subtotal gastrectomy: a prospective, randomized, double-blind, placebo-controlled study. Can J Surg. 2014;57:175–21.
11. Zhao JB, Li YL, Wang YM, et al. Intravenous lidocaine infusion for pain control after laparoscopic cholecystectomy: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97:e9771.
12. Stroumpos C, Manolaraki M, Paspatis GA. Remifentanil, a different opioid: potential clinical applications and safety aspects. Expert Opin Drug Saf. 2010;9:355–64.
13. Ho M, Kerr SJ, Stevens J. Intravenous lidocaine infusions for 48 hours in open colorectal surgery: a prospective, randomized, double-blinded, placebo-controlled trial. Korean J Anesthesiol. 2018;71:57–65.
14. Sloan TB, Mongan P, Lyda C, et al. Lidocaine infusion adjunct to total intravenous anesthesia reduces the total dose of propofol during intraoperative neurophysiological monitoring. J Clin Monit Comput. 2014;28:139–47.
15. Ibrahim A, Aly M, Farrag W. Effect of intravenous lidocaine infusion on long-term postoperative pain after spinal fusion surgery. Medicine (Baltimore). 2018;97:e229.
16. Nakhil MS, Kahloul M, Guizani T, et al. Intravenous lidocaine as adjuvant to general anesthesia in renal surgery. Libyan J Med. 2018;13:1433418.
17. Xu SQ, Li YH, Wang SB, et al. Effects of intravenous lidocaine, dexmedetomidine and their combination on postoperative pain and bowel function recovery after abdominal hysterectomy. Minerva Anestesiol. 2017;83:685–94.
18. Cui W, Li Y, Li S, et al. Systemic administration of lidocaine reduces morphine requirements and postoperative pain of patients undergoing thoracic surgery after propofol-remifentanil-based anaesthesia. Eur J Anaesthesiol. 2010;27:41–6.
19. Uzun S, Yuce Y, Erden A, et al. Impact of perioperative lidocaine infusion and bis monitoring on remifentanil dosage in hypotensive anesthesia. Eur Rev Med Pharmacol Sci. 2014;18:559–65.
20. Tanaka Y, Nakayama T, Nishimori M, et al. Lidocaine for preventing postoperative sore throat. Cochrane Database Syst Rev. 2009;(3):CD004081.
21. Gholipour BA, Firoozian A, Hasanzadeh KF, et al. Bolus administration of intravenous lidocaine reduces pain after an elective caesarean section: Findings from a randomised, double-blind, placebo-controlled trial. J Obstet Gynaecol. 2017;37:566–70.
22. Farag E, Ghoibrial M, Sessler DI, et al. Effect of perioperative intravenous lidocaine administration on pain, opioid consumption, and quality of life after complex spine surgery. Anesthesiology. 2013;119:932–40.
23. Kaba A, Laurent SR, Detroz BJ, et al. Intravenous lidocaine infusion facilitates acute rehabilitation after laparoscopic colectomy. Anesthesiology. 2007;106, 11–18, 5–6.
24. Bazin P, Padley J, Ho M, et al. The effect of intravenous lidocaine infusion on bispectral index during major abdominal surgery. J Clin Monit Comput. 2018;32:533–9.